Pharmacology and pharmacokinetics of citalopram and other SSRIs

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 1, 1996, Pages 5-11

  Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Chiral compounds; Cytochrome P450; Depressive patients; Pharmacogenetics; Pharmacokinetics; Serotonin receptors; Serotonin uptake; SSRIs; Therapeutic drug monitoring

Indexed keywords

CITALOPRAM; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

BRAIN SYNAPTOSOME; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; ENZYME INHIBITION; HUMAN; NONHUMAN; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; SEROTONIN UPTAKE;

ANIMALS; BRAIN; CITALOPRAM; HUMANS; NOREPINEPHRINE; RATS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES;

EID: 0029940102     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199603001-00002     Document Type: Article

References (63)

1. 1A agonist, in major depression: effects on sleep REM latency and body temperature. Human Psychopharmacology, 8, 279-283.
2. Baettig D, Bondolfi G, Montaldi S, Amey M and Baumann P (1993) Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. European Journal of Clinical Pharmacology, 44, 403-405.
3. Banerjee SP, Kung LS, Riggi SJ and Chanda SK (1977) Development of β-adrenergic receptor subsensitivity by antidepressants. Nature, 268, 455-456.
4. Barr LC, Goodman WK and Price LH (1994) Physical symptoms associated with paroxetine discontinuation. American Journal of Psychiatry, 151, 289.
5. Baumann P (1992) Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). International Clinical Psychopharmacology, 6 (suppl 5), 13-20.
6. Baumann P and Larsen F (1995) The pharmacokinetics of citalopram. Reviews in Contemporary Pharmacotherapy, 6, 287-295.
7. Baumann P and Rochat B (1995) Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. International Clinical Psychopharmacology, 10 (suppl 1), 15-21.
8. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M and Jonzier-Perey M (1996) A double-blind placebo controlled study of CIT with and without lithium in the treatment of therapy-resistant depressive patients. A clinical pharmacokinetic and pharmacogenetic investigation. Journal of Clinical Psychopharmacology, in press.
9. Beasley CM Jr, Bosomworth JC and Wernicke JF (1990) Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacology Bulletin, 26, 18-24.
10. Beasley CM, Masica DN and Potvin JH (1992) Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology, 107, 1-10.
11. Bertschy G, Vandel S, Vandel B, Allers G and Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction - an accidental finding. European Journal of Clinical Pharmacology, 40, 119-120.
12. Black DW, Wesner R and Gabel J (1993) The abrupt discontinuation of fluvoxamine in patients with panic disorder. Journal of Clinical Psychiatry, 54, 146-149.
13. Bolden-Watson C and Richelson E (1993) Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences, 52, 1023-1029.
14. Brøsen K (1993) The pharmacogenetics of the selective serotonin reuptake inhibitors. Clinical Investigator, 71, 1002-1009.
15. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE and Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochemical Pharmacology, 45, 1211-1214.
16. Conus P, Bondolfi G, Eap CB, Macciardi F and Baumann P (1996) A pharmacokinetic fluvoxamine-clomipramine interaction with favourable therapeutic consequences in a therapy-resistant depressive patient. Pharmacopsychiatry, in press.
17. DeVane CL (1994) Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55, 38-45.
18. Dubovsky SL and Thomas M (1995) Serotonergic mechanisms and current and future psychiatric practice. Journal of Clinical Psychiatry, 56 (suppl 2), 38-48.
19. Dufour H, Bouchacourt M, Thermoz P, Viala A, Pok Phak Rop, Gouezo F, Durand A and Petersen HEH (1987) Citalopram - a highly selective 5-HT uptake inhibitor in the treatment of depressed patients. International Clinical Psychopharmacology, 2, 225-237.
20. Frost L and Lal S (1995) Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. American Journal of Psychiatry, 152, 810.
21. Fuller RW, Snoddy HD, Krushinski JH and Robertson DW (1992) Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology, 31, 997-1000.
22. Fuller RW, Hemrick-Luecke SK, Littlefield ES and Audia JE (1995) Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19, 135-149.
23. Goodnick PJ (1994) Pharmacokinetic optimisation of therapy with newer antidepressants. Clinical Pharmacokinetics, 27, 307-330.
24. Gram LF, Hansen MGJ, Sindrup SH, Brøsen K, Poulsen JH, Aaes-Jørgensen T and Overø KF (1993) Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Therapeutic Drug Monitoring, 15, 18-24.
25. Gupta RN and Dziurdzy SA (1994) Therapeutic monitoring of sertraline. Clinical Chemistry, 40, 498-499.
26. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H and Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. Journal of Clinical Psychopharmacology, 14, 279-281.
27. Hjorth S and Auerbach SB (1994) Lack of 5-HT (1A) autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology, 33, 331-334.
28. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology, 9 (suppl 1), 19-26.
29. Hyttel J, Bogeso KP, Perregaard J and Sanchez C (1992) The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. Journal of Neural Transmission, 88, 157-160.
30. Hyttel J, Arnt J and Sanchez C (1995) The pharmacology of citalopram. Reviews in Contemporary Pharmacotherapy, 6, 271-285.
31. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD and Greb WH (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatrica Scandinavica, 80 (suppl 350), 60-75.
32. Koe BK (1990) Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. Journal of Clinical Psychiatry, 51 (suppl B), 13-17.
33. Leonard BE (1994) Serotonin receptors - where are they going? International Clinical Psychopharmacology, 9 (suppl 1), 7-17.
34. Louie AK, Lannon RA and Ajari LJ (1994) Withdrawal reaction after sertraline discontinuation. American Journal of Psychiatry, 151, 450-451.
35. 4 receptors. British Journal of Pharmacology, 114, 1017-1025.
36. Luo H and Richardson JS (1993) A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. International Clinical Psychopharmacology, 8, 3-12.
37. Meyer UA (1994) The molecular basis of genetic polymorphisms of drug metabolism. Journal of Pharmacy and Pharmacology, 46 (suppl 1), 409-415.
38. Mishra R, Janowsky A and Sulser F (1979) Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in brain: effects of nisoxetine versus fluoxetine. European Journal of Pharmacology, 60, 379-382.
39. Nalepa I and Vetulani J (1993) Enhancement of the responsiveness of cortical adrenergic receptors by chronic administration of the 5-hydroxytryptamine uptake inhibitor citalopram. Journal of Neurochemistry, 60, 2029-2035.
40. Newman ME, Lerer B and Shapira B (1993) 5-HT-1A receptor-mediated effects of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 17, 1-20.
41. Norman TR, Gupta RK, Burrows GD, Parker G and Judd FK (1993) Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. International Clinical Psychopharmacology, 8, 25-29.
42. Paul IA, Nowak G, Layer RT, Popik P and Skolnick P (1994) Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. Journal of Pharmacology and Experimental Therapeutics, 269, 95-109.
43. Peroutka SJ (1994) Molecular biology of serotonin (5-HT) receptors. Synapse, 18, 241-260.
44. Perucca E, Gatti G and Spina E (1994) Clinical pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics, 27, 175-190.
45. Preskorn SH and Magnus RD (1994) Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacology Bulletin, 30, 251-259.
46. Richelson E (1994a) Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clinic Proceedings, 69, 1069-1081.
47. Richelson E (1994b) The pharmacology of antidepressants at the synapse: focus on newer compounds. Journal of Clinical Psychiatry, 55 (suppl A), 34-39.
48. Rochat B, Amey M and Baumann P (1995) Analysis of the enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Therapeutic Drug Monitoring, 17, 273-279.
49. Scatton B (1993) The NMDA receptor complex. Fundamental Clinical Pharmacology, 7, 389-400.
50. Seifritz E, Baumann P, Müller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F and Holsboer-Trachsler E (1996) Neuroendocrine effects of citalopram short-infusion in healthy males: a placebo controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology, in press.
51. Silver H, Kaplan A and Jahjah N (1995) Fluvoxamine augmentation for clozapine-resistant schizophrenia. American Journal of Psychiatry, 152, 1098.
52. Sindrup SH, Brøsen K, Hansen MGL, Aaes-Jørgensen T, Overø KF and Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Therapeutic Drug Monitoring, 15, 11-17.
53. Sleight AJ, Carolo C, Petit N, Zwingelstein C and Bourson A (1995) Identification of 5-hydroxytryptamine(7) receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. Molecular Pharmacology, 47, 99-103.
54. Stoukides JA and Stoukides CA (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine. American Journal of Psychiatry, 148, 1263.
55. Szegedi A, Wiesner J and Hiemke C (1995) Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. Journal of Clinical Psychopharmacology, 15, 141-143.
56. Torok-Both GA, Baker GB, Coutts RT, McKenna KF and Aspeslet LJ ( 1992) Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. Journal of Chromatography and Biomedical Applications, 579, 99-106.
57. Vandel S, Bertschy G, Bouquet S, Bonin B and Vittouris N (1994) Fluoxetine and norfluoxetine plasma levels after treatment discontinuation in man. Therapie, 49, 141-142.
58. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, François T, Sechter D and Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine, and neuroleptics in phenotyped patients. Pharmacology Research, 31, 347-353.
59. Van Harten J (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 24, 1-18.
60. Vetulani J, Stawarz RJ, Dingell JV and Sulser F (1976) A possible common mechanism of action of antidepressant treatments-reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn-Schmiedeberg's Archives of Pharmacology, 293, 109-114.
61. Wander TJ, Nelson A, Okazaki H and Richelson E (1986) Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. European Journal of Pharmacology, 132, 115-121.
62. Wong DT, Fuller RW and Robertson DW (1990) Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharmaceutica Nordica, 2, 171-179.
63. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH and Robertson DW (1993) Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology, 8, 337-344.